The Digenic Causality in Familial Hypercholesterolemia: Revising the Genotype–Phenotype Correlations of the Disease
Open Access
- 15 January 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 11
Abstract
Genetically inherited defects in lipoprotein metabolism affect more than 10 million individuals around the globe with preponderance in some parts where consanguinity played a major role in establishing founder mutations. Mutations in four genes have been so far linked to the dominant and recessive form of the disease. Those players encode major proteins implicated in cholesterol regulation, namely, the low-density lipoprotein receptor (LDLR) and its associate protein 1 (LDLRAP1), the proprotein convertase substilin/kexin type 9 (PCSK9), and the apolipoprotein B (APOB). Single mutations or compound mutations in one of these genes are enough to account for a spectrum of mild to severe phenotypes. However, recently several reports have identified digenic mutations in familial cases that do not necessarily reflect a much severe phenotype. Yet, data in the literature supporting this notion are still lacking. Herein, we review all the reported cases of digenic mutations focusing on the biological impact of gene dosage and the potential protective effects of single-nucleotide polymorphisms linked to hypolipidemia. We also highlight the difficulty of establishing phenotype–genotype correlations in digenic familial hypercholesterolemia cases due to the complexity and heterogeneity of the phenotypes and the still faulty in silico pathogenicity scoring system. We finally emphasize the importance of having a whole exome/genome sequencing approach for all familial cases of familial hyperlipidemia to better understand the genetic and clinical course of the disease.Keywords
This publication has 110 references indexed in Scilit:
- Digenic inheritance in medical geneticsJournal of Medical Genetics, 2013
- Genome-Wide Linkage Scan of a Pedigree with Familial Hypercholesterolemia Suggests Susceptibility Loci on Chromosomes 3q25-26 and 21q22PLOS ONE, 2011
- Familial Hypercholesterolemia: The Lipids or the Genes?Nutrition & Metabolism, 2011
- Modifier genes in Mendelian disorders: the example of cystic fibrosisAnnals of the New York Academy of Sciences, 2010
- The genetic basis of familial hypercholesterolemia: inheritance, linkage, and mutationsThe Application of Clinical Genetics, 2010
- The Type of LDLR Gene Mutation Predicts Cardiovascular Risk in Children with Familial HypercholesterolemiaThe Journal of Pediatrics, 2009
- Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart DiseaseNew England Journal of Medicine, 2006
- Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9Proceedings of the National Academy of Sciences, 2005
- Independent Mutations at Codon 3500 of the Apolipoprotein B Gene Are Associated With HyperlipidemiaArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- The familial hypercholesterolemia (FH)-North Karelia mutation of the low density lipoprotein receptor gene deletes seven nucleotides of exon 6 and is a common cause of FH in Finland.Journal of Clinical Investigation, 1992